Pharmaceuticals
Piramal Pharma Solutions recognized by Frost & Sullivan for its End-to-End Integrated Services Across the Entire Drug Development Life Cycle
SANTA CLARA, California, June 18, 2019 /PRNewswire/ -- Based on its recent analysis of the contract development and manufacturing organization market, Frost & Sullivan recognized Piramal Pharma Solutions ('PPS', 'the business') with the 2019 Global Customer Service Leadership Award. Through its 1...
2019-06-18 20:00
454
Seegene Establishes Brazilian Subsidiary
SEOUL, South Korea, June 18, 2019 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered inSouth Korea, announced today the formation of a new subsidiary, Seegene do Brasil Diagnosticos Ltda., inBelo Horizonte, Brazil. Seegene do Brasil Diagnos...
2019-06-18 19:00
266
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings
SUZHOU, China, June 18, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the clinical results of CT103A, the potential best-in-class therapy of fully-human ...
2019-06-18 08:00
872
China National Medical Products Administration Approves Sinovant's Clinical Trial Application for Lefamulin
- Chinese registrational clinical trial for lefamulin to begin in 2H 2019 BEIJING and SHANGHAI, June 14, 2019 /PRNewswire/ -- Sinovant Sciences today announced that its Clinical Trial Application (CTA) for lefamulin has been accepted by the Center for Drug Evaluation at the China National Medica...
2019-06-14 09:00
1668
Tessa Therapeutics and China-Singapore Guangzhou Knowledge City Form Landmark US$120 Million Joint Venture in China to Develop Innovative Cell Therapies for Cancer
* The partnership will leverage Tessa Therapeutics' global operational capabilities and cell therapy platform technologies to target prevalent cancers inChina * The joint venture will be the sole licensee of Tessa Therapeutics' cell therapies for research, development and commercialization in...
2019-06-13 07:15
1132
Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
SAN FRANCISCO, June 12, 2019 /PRNewswire/ -- Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The p...
2019-06-12 02:45
1528
Amcor Completes Acquisition of Bemis, Creating the Global Leader in Consumer Packaging
CHICAGO and MELBOURNE, Australia, June 12, 2019 /PRNewswire/ -- Amcor today announces the successful completion of its acquisition of Bemis Company Inc., effective11 June 2019. The combined company will now operate as Amcor plc (Amcor), trading on the New York Stock Exchange under the ticker symb...
2019-06-12 02:26
1481
TauRx Recognized as a Technology Innovation Leader in the Neurodegenerative Disease Management Industry
ABERDEEN, Scotland and SINGAPORE, June 11, 2019 /PRNewswire/ -- TauRx, a leader
in neurodegenerative disease research, today announced that it is the recipient
of Frost & Sullivan's 2019 Asia Pacific Neurodegenerative Disease Management
Technology Innovation Award.
2019-06-11 08:00
1253
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
PLYMOUTH MEETING, Pennsylvania, June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Medical ...
2019-06-10 21:00
1485
Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks
Abstracts 54-OR and 55-OR Secondary data at 52 weeks demonstrated statistically significant blood sugar reductions and statistically significant reduction of body weight vs both Jardiance® and Victoza® SAN FRANCISCO, June 8, 2019 /PRNewswire/ -- Findings presented today from two phase 3a clinic...
2019-06-08 23:45
2342
ESPGHAN Researchers Warn: Junk Food Could Be Responsible for the Food Allergy Epidemic
GLASGOW, Scotland, June 8, 2019 /PRNewswire/ -- Experts at the 52nd Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) are today presenting research that shows higher levels of advanced glycation end products (AGEs), found in abundance in ju...
2019-06-08 07:01
3004
Innovent provides Update on the Results of Sintilimab for the Treatment of Extranodal NK/T Cell Lymphoma by Oral Presentation at ASCO
SUZHOU, China, June 5, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the research data on the treatment of relapsed or refractory extranodal NK/T cell ly...
2019-06-05 08:00
1978
RemeGen, Ltd. Announces Positive Results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer
Results, presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated clinically meaningful response in patients with urothelial carcinoma whose treatment previously failed, a population with high unmet medical need YANTAI, China, June 4, 2019 /PRNewswire/ -- R...
2019-06-04 21:00
2031
Innovent Provides Update on ctDNA in Predicting Response and Resistance by Anti-PD-1 Therapy in Chinese Relapsed/Refractory Classical Hodgkin Lymphoma
SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of circulating tumor DNA (ctDNA) for predicting response and resistance ...
2019-06-04 08:00
1911
Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma
SUZHOU, China, June 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of extended follow-up on sintilimab, the anti-PD-1 antibody that co-deve...
2019-06-04 08:00
7845
Innovent Provides Update on Sintilimab in Combination with CAPOX for First-Line Treatment of Patients with Gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)
SUZHOU, China, June 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the preliminary results of efficacy and safety of sintilimab, the anti-PD-1 antibody...
2019-06-04 08:00
7902
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations
ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media DARMSTADT, Germany, June 4, 2019 /PRNewswire/ -- * Alterations of the MET signaling pathway are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis * N...
2019-06-04 02:16
1837
Frost & Sullivan Publishes Q1 Update on Kadimastem
Continues its plans as expected; Ministry of Health approval for central experiment; financing is required to continue operations at the beginning of 2020; received Orphan Drug Designation from the FDA; target price unchanged. TEL AVIV, Israel, June 3, 2019 /PRNewswire/ -- The TASE analysis proje...
2019-06-03 21:24
1154
Updated Results on Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Squamous Non-Small Cell Lung Cancer (sqNSCLC) at ASCO, Led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences
SUZHOU, China, June 3, 2019 /PRNewswire/ -- The preliminary results of efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC) (ChiCTR-OIC-17013726), led by ProfessorJie He, Dean of the Cancer Hospital of the Chinese Academy of ...
2019-06-03 08:00
10223
Innovent Provides Key Results Update of IBI305 (Biosimilar Product Candidate of Bevacizumab) Compared with Bevacizumab
SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the study results for efficacy and safety of IBI305 (biosimilar of bevacizumab) comp...
2019-06-03 08:00
1509
Week's Top Stories
Most Reposted
Emaar Hospitality Group Unveils Vida Emirates Hills, an Upscale Lifestyle Hotel in a Tranquil Setting
[Picked up by 116 media titles]
2019-06-13 16:12
Artprice: A Masterpiece by Caravaggio, a Monet, a Bacon and a Small Basquiat to Close Out H1 2019
[Picked up by 102 media titles]
2019-06-13 00:07
New World Facilities Management Company Limited Receives Hong Kong General Chamber of Small and Medium Business Ltd.'s Best SME's Partner Award Again
[Picked up by 94 media titles]
2019-06-12 15:36
Vera's First Assignment: Volvo Trucks Presents an Autonomous Transport Between a Logistics Centre and Port
[Picked up by 93 media titles]
2019-06-13 15:00
Superloop leverages HPE OEM Partnership to launch latest cybersecurity innovation to protect school networks.
[Picked up by 92 media titles]
2019-06-12 05:07
Most Read
LITE-ON Aims to Expand Vietnam Market with IIoT Gateway Solution
2019-06-12 12:49
6548
Fang and China Index Announce Completion of Separation by Way of Distribution
2019-06-13 07:29
6473
Renren Announces Unaudited First Quarter 2019 Financial Results
2019-06-12 06:00
6234